Johnson & Johnson (NYSE:JNJ) Shares Acquired by Venture Visionary Partners LLC
Venture Visionary Partners LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 15.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,213 shares of the company’s stock after buying an additional 3,000 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Venture Visionary Partners LLC’s holdings, making the stock its 22nd largest position. Venture Visionary Partners LLC’s holdings in Johnson & Johnson were worth $2,912,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $4,139,107,000. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 77.4% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,725,664 shares of the company’s stock valued at $689,332,000 after purchasing an additional 2,061,958 shares during the last quarter. M&G Investment Management Ltd. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $269,234,000. Alliancebernstein L.P. lifted its holdings in shares of Johnson & Johnson by 20.5% during the fourth quarter. Alliancebernstein L.P. now owns 9,399,325 shares of the company’s stock valued at $1,371,080,000 after purchasing an additional 1,599,581 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock valued at $5,589,167,000 after purchasing an additional 1,364,028 shares during the last quarter. 67.66% of the stock is owned by institutional investors and hedge funds.
Shares of JNJ stock opened at $144.37 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The stock’s 50-day moving average is $146.81 and its two-hundred day moving average is $142.30. The firm has a market cap of $386.52 billion, a P/E ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date is Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.80%. Johnson & Johnson’s dividend payout ratio is currently 43.78%.
JNJ has been the subject of several research analyst reports. Argus reissued a “buy” rating and issued a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Morgan Stanley increased their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Credit Suisse Group reissued a “buy” rating and issued a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Finally, UBS Group downgraded Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average target price of $163.47.
In related news, Director William D. Perez acquired 500 shares of the stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is the downside to momentum investing?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.